Andreas Penk, MD
The European Commission has approved PF-06439535 (Zirabev), a bevacizumab (Avastin) biosimilar for the treatment of patients with metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic, or recurrent non–small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer, and persistent recurrent or metastatic carcinoma of the cervix.1
- Pfizer receives European Approval for ZIRABEV (bevacizumab), a biosimilar to Avastin. Pfizer. Published February 19, 2019. https://on.pfizer.com/2BMbr8d. Accessed February 19, 2019.
- Socinski MA, Von Pawel J, Kasahara K, et al. A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non–small cell lung cancer. J Clin Oncol. 2018;36(suppl 15, abstr 109). doi: 10.1200/JCO.2018,36,15_suppl.109.
- Knight B, Rassam D, Liao S, et al. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839-46. doi: 10.1007/s00280-016-3001-2.
... to read the full story